The influence of bisoprolol dose on ADP-induced platelet aggregability in patients on dual antiplatelet therapy.
OBJECTIVE
Dual antiplatelet therapy is recommended after acute coronary syndrome or after percutaneous coronary intervention with coronary stent implantation. Many of the patients on dual antiplatelet therapy receive β-blockers; some of them could have antiaggregatory effect. Bisoprolol is a highly selective adrenoceptor-blocker, which is often used in the settings of percutaneous coronary intervention or acute coronary syndrome in patients on dual antiplatelet therapy. Its antiaggregative effect has not been extensively studied. Therefore, the aim of this study is to investigate the effect of bisoprolol on ADP-induced platelet aggregation in patients on dual antiplatelet therapy.


METHODS
Platelet aggregability has been measured in 100 patients on dual antiplatelet therapy with multiplate analyzer using ADP test in blood samples anticoagulated with heparin. ADP test values have been expressed by arbitrary units/minute. In univariate and multivariate regression analyses, we have investigated the influence of bisoprolol and its dose and also different factors, such as risk factors, concomitant drugs and their dosage, laboratory findings, on ADP test values.


RESULTS
Univariate regression analysis showed significant correlation between the bisoprolol dose and the ADP test value (P=0.046, B=52.55, 95% confidence interval 0.87-104.23), which was also shown in the multivariate regression analysis (P=0.018; B=57.011; 95% confidence interval 10.455-103.567).


CONCLUSIONS
We have identified a positive correlation between bisoprolol dose and ADP-induced platelet aggregability in patients on dual antiplatelet therapy.
Ignjatovic
Vladimir Slavisa
VS
Clinical Center Kragujevac, Zmaj Jovina, Serbia. vladaig@yahoo.com
Petrovic
Njegos
N
Miloradovic
Vladimir
V
Ignjatovic
Snezana
S
Cokanovic
Vesna
V
Grdinic
Aleksandra
A
Simic
Ivan
I
Petrovic
Ivica
I
Nikolic
Sara
S
Andjelkovic
Aleksandar
A
Paramentic
Dusan
D
Ignjatovic
Slavisa
S
D000244:Adenosine Diphosphate; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation; D017298:Bisoprolol / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors; D055771:Serbia; D015607:Stents
D058671:Adrenergic beta-1 Receptor Antagonists; D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D017298:Bisoprolol